Clinical trial
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With…
NCT00111449 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111449 |
|---|---|
| Title | Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis |
| Official title | A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis |
| Lead sponsor | Amgen, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 600 |
| Start date | Jun 1, 2003 |
| First posted | May 23, 2005 |
| Last update posted | May 15, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: